BBL
IRD

Beck Bode LLC’s Opus Genetics IRD Stock Holding History

Beck Bode LLC’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed – – 295
2020
Q3 		$0 Buy
+2
New +$19 ﹤0.01% 323

Other funds holding IRD

ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Beck Bode LLC's IRD Position: Q4 2020 in Review

Beck Bode LLC sold out of Opus Genetics (IRD) in Q4 2020, closing a stake of 2 shares.

Beck Bode LLC first reported a position in IRD in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 14 funds tracked by Wall St. Rank hold IRD as of Q4 2020.

  • Beck Bode LLC reported no remaining Opus Genetics position as of Q4 2020 after selling out during the quarter.
  • Beck Bode LLC sold 2 Opus Genetics shares in Q4 2020.
  • Beck Bode LLC first reported a position in Opus Genetics in Q3 2020 and held it in 1 quarter.
  • Beck Bode LLC's Opus Genetics position peaked at $0 in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2020.

Based on Beck Bode LLC's 13F filing for Q4 2020.